

# Malaga Spain IUPHAR Mentoring Center

## Site

Pharmacology, Toxicology and Therapeutics, University of Malaga, Instituto de Investigación Biomédica de Málaga (IBIMA). Malaga, Spain

## Address

Facultad de Medicina, Blvd L Pasteur 32, 29071 Malaga

## Contact

email to Prof M Isabel Lucena [lucena@uma.es](mailto:lucena@uma.es)

## Affiliations

- Clinical Trials Unit for promoting and conducting Independent Clinical Research
- Spanish Network on Addiction Research since 2003. Founder & Coordination.
- Center for Biomedical Research in Digestive and Liver Diseases (Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas, CIBERehd) since 2008
- Spanish Medicines Agency (Agencia Española de Medicamento y Productos Sanitarios, AEMP), consultant group for the pharmacoepidemiology and pharmacovigilance department and the Committee on Drug Evaluation since 1999
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, ENCePP, supported by the European Medicines Agency since its foundation

## Key individuals (and expertise)

- Prof. Emilio Alba, Oncology, translational research and clinical trials
- Prof. Raúl J Andrade Clinical & translational research in toxic, infectious, immunological and metabolic liver damage.
- Prof. M. Isabel Lucena, Clinical Pharmacology, pharmacoepidemiology & pharmacovigilance, Drug development and Clinical Evaluation drug efficacy, Safety, Pharmacoeconomics
- Prof. Aurelio Gomez-Luque, Anesthesia, Pain, translational research & clinical trials
- Prof. Fernando Rodriguez de Fonseca, Clinical Toxicology, Drug addiction and alcoholism, Neurobiology, Development of novel therapeutic approaches

## Research Expertise

- Clinical trials
- Clinical toxicology
- Biomarkers
- Pharmacogenetics,
- Flow cytometry assays in clinical studies
- Integration of OMICs through systems biology
- Education, Innovative approaches
- Oncology, First-in-humans studies
- Idiosyncratic drug induced liver injury
- Clinical research techniques- protocol design; in depth phenotyping, selection of

- outcome measures, liver function
- Validation of new drug targets in preclinical models

### Opportunities on offer

- Email/skype advice on clinical research study design and monitoring
- Email/skype advice on research in our areas of expertise
- Email/skype advice on educational/curricular plans and doctorate courses
- Email/Skype on drug development
- Email/skype on setting up a registry
- Potential relevant collaborations in areas of mutual interest
- Willingness to host self-funded visitors/fellowships in areas of mutual interest

### Selected Publications

1. Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. *Oncologist*. 2016 Feb;21(2):150-5. PMID: 26786263
2. Pajares B, Trigo JM, Toledo MD, Álvarez M, González-Hermoso C, Rueda A, Medina JA, de Luque V, Jerez JM, Alba E. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. *BMC Cancer*. 2013 Jan 18;13:26. PMID: 23331666.
3. Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo JA, Rodriguez-Martin C, Escudero MJ, Albanell J. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. *Breast Cancer Res Treat*. 2012 Nov;136(2):487-93. PMID: 23053638.
4. Romero-Gómez M, Del Mar Vioria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*. 2014 Jul;147(1):109-118. PMID: 24704526.
5. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*. 2011 Jul;141(1):338-47. PMID: 21570397.
6. Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R;

- TeraViC-4 Study Group. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. *Gastroenterology*. 2006 Aug;131(2):451-60. PMID: 16890599.
7. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients *Gastroenterology*. 2005 Mar;128(3):636-41. PMID: 15765399.
  8. Robles-Díaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jiménez A, Ulzurrun E, Gonzalez AF, Fernandez MC, Romero-Gómez M, Jimenez-Perez M, Bruguera M, Prieto M, Bessone F, Hernandez N, Arrese M1, Andrade RJ; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology*. 2005 Aug;129(2):512-21. PMID: 16083708.
  9. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borrás A, Soler A, Salmerón J, Martín-Vivaldi R; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period *Gastroenterology*. 2005 Aug;129(2):512-21. PMID: 16083708.
  10. Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D. An anorexic lipid mediator regulated by feeding. *Nature*. 2001 Nov 8;414(6860):209-12. PMID: 11700558.
  11. Muñoz M, Gómez-Luque A, Naveira-Abeigón E, Ramírez G. Erythrocyte transfusion and postsurgical morbidity in cardiac surgery patients: is it the storage time or the number of transfused concentrates that really matters? *Anesthesiology*. 2004 Jan;100(1):193-4; PMID: 14695747
  12. Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodríguez de Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. *J Neurosci*. 2002 Nov 1;22(21):9612-7. PMID: 12417686.
  13. Bellido I, Gomez-Luque A, Garcia-Carrera P, Rius F, de la Cuesta FS. Female rats show an increased sensibility to the forced swim test depressive-like stimulus in the hippocampus and frontal cortex 5-HT1A receptors. *Neurosci Lett*. 2003 Oct 30;350(3):145-8. PMID: 14550915
  14. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature*. 2003 Sep 4;425(6953):90-3. PMID: 12955147.
  15. Bermúdez-Silva FJ, Suárez J, Baixeras E, Cobo N, Bautista D, Cuesta-Muñoz AL, Fuentes E, Juan-Pico P, Castro MJ, Milman G, Mechoulam R, Nadal A, Rodríguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. *Diabetologia*. 2008 Mar;51(3):476-87. PMID: 18092149.
  16. Serrano A, Pavón FJ, Suarez J, Rivera P, Vida M, Bermúdez-Silva FJ, Alonso M, Martínez A, López-Ogalla J, Alonso-Gascón M, Santamaría G, Romero-Cuevas M,

Pérez-Valero V, Baixeras E, Rodríguez de Fonseca F. Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. *Am J Physiol Endocrinol Metab.* 2012 Apr 1;302(7):E817-30. PMID: 22297300.